Amid efforts to blunt rising medicines costs, a new analysis finds three states succeeded in helping their residents save money by capping out-of-pocket costs on pricey specialty drugs and, at the same time, also managed to avoid increased spending by health plans.
Overall, out-of-pocket spending by patients fell $351 per month in Delaware, Maryland, and Louisiana, each of which passed laws that set $150 caps on what consumers must pay for prescriptions for specialty medicines. These include medications to combat such hard-to-treat maladies as multiple sclerosis, rheumatoid arthritis, and hepatitis C, among others.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Once a patient reaches the cap, which entity absorbes the loss from the reduced co-pay contribution?
I don’ know – but I am guessing the insurers just get less out-of-pocket money from patients.